{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:28:00Z","timestamp":1793863680056,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Race Against Dementia Alzheimer\u2019s Research UK","award":["ARUK-RADF2021A-010"],"award-info":[{"award-number":["ARUK-RADF2021A-010"]}]},{"name":"Parke Davis Exchange Fellowship in Biomedical Sciences","award":["PD\/2020\/02"],"award-info":[{"award-number":["PD\/2020\/02"]}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203312"],"award-info":[{"award-number":["NIHR203312"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NIA","award":["P30-AG062422, R35 AG072362, U01-AG057195, U01-AG082350"],"award-info":[{"award-number":["P30-AG062422, R35 AG072362, U01-AG057195, U01-AG082350"]}]},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009825","name":"American College of Radiology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009825","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016608","name":"Rainwater Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029137","name":"Laurel Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100029137","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shenandoah Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tau-PET binding patterns are heterogenous, with regional binding showing strong cross-sectional correlations with domain-specific cognitive performance and longitudinal correlations with prospective neurodegeneration. Here we evaluated whether regional patterns of baseline tau-PET predict prospective longitudinal decline in specific cognitive domains in early symptomatic Alzheimer\u2019s disease (AD), including participants from clinical trial cohorts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>731 amyloid-positive participants with a clinical diagnosis of mild cognitive impairment (MCI) or mild AD dementia underwent a flortaucipir F 18 PET (FTP-PET), structural MRI, and neuropsychological testing with the AD Assessment Scale-Cognitive Subscale (ADAS-Cog). Cognitive assessment was repeated after 9\u201318 or 12\u201324 months. Sub-scale annualized w-scores at each time point were combined as composite scores according to domains, including episodic memory, semantic memory, executive function, language and praxis. Latent growth curve models were applied to longitudinal composite scores to estimate the rate of annual decline (slope) in each participant. Standardized uptake value ratio (SUVR) images were created using cerebellar crus as the reference region. Regional and voxel-wise correlation analyses were implemented to identify baseline FTP-PET patterns and MRI grey matter volumes associated with longitudinal changes in each cognitive domain, and to evaluate whether MRI mediates the association between FTP-PET and cognitive decline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Differential FTP-PET signal patterns showed significant negative associations with domain-specific annual rates of decline. Higher temporo-parietal FTP-PET SUVR was associated with faster decline in episodic memory, while higher left anterior temporal SUVR was associated with faster decline in semantic memory. FTP-PET signal in a left-dominant fronto-temporal pattern was associated with faster decline in language, while FTP-PET signal in a right-dominant fronto-parietal pattern was associated with faster decline in praxis. Executive decline showed limited spatial associations with FTP-PET. Overall, regional and voxel-wise analyses identified similar pairwise associations between FTP-PET signal and domain-specific longitudinal decline. Baseline MRI showed weaker associations with domain-specific cognitive decline than FTP-PET, and did not mediate the predictive effect of the latter.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Differential regional tau-PET signal patterns were associated with domain-specific cognitive decline in MCI and early AD dementia. Tau-PET may be a useful precision medicine tool to support individualized predictions of cognitive decline trajectories in early symptomatic AD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13195-025-01868-7","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:47:18Z","timestamp":1759754838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Regional tau PET patterns predict prospective domain-specific cognitive decline in early symptomatic Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Maura","family":"Malpetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"La Joie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tronchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alette M.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pontecorvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Shcherbinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil D.","family":"Rabinovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"1868_CR1","doi-asserted-by":"publisher","first-page":"830","DOI":"10.2967\/jnumed.121.263694","volume":"63","author":"M Malpetti","year":"2022","unstructured":"Malpetti M, Joie R, La, Rabinovici GD. Tau beats amyloid in predicting brain atrophy in alzheimer disease: implications for prognosis and clinical trials. J Nucl Med. 2022;63:830\u20132.","journal-title":"J Nucl Med"},{"key":"1868_CR2","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/brain\/awz090","volume":"142","author":"MJ Pontecorvo","year":"2019","unstructured":"Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and alzheimer\u2019s disease dementia. Brain. 2019;142:1723\u201335.","journal-title":"Brain"},{"key":"1868_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol. 2012;71:362\u201381.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1868_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cercor\/bhaa184","volume":"31","author":"L Iaccarino","year":"2021","unstructured":"Iaccarino L, La Joie R, Edwards L, Strom A, Schonhaut DR, Ossenkoppele R, et al. Spatial relationships between molecular pathology and neurodegeneration in the alzheimer\u2019s disease continuum. Cereb Cortex. 2021;31:1\u201314.","journal-title":"Cereb Cortex"},{"key":"1868_CR5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in alzheimer\u2019s disease. Brain. 2016;139:1551\u201367.","journal-title":"Brain"},{"key":"1868_CR6","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","volume":"140","author":"A Bejanin","year":"2017","unstructured":"Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in alzheimer\u2019s disease. Brain. 2017;140:3286\u2013300.","journal-title":"Brain"},{"key":"1868_CR7","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","volume":"92","author":"R Ossenkoppele","year":"2019","unstructured":"Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, et al. Associations between tau, A\u03b2, and cortical thickness with cognition in alzheimer disease. Neurology. 2019;92:e601\u201312.","journal-title":"Neurology"},{"key":"1868_CR8","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1093\/brain\/awac229","volume":"145","author":"JA Tanner","year":"2022","unstructured":"Tanner JA, Iaccarino L, Edwards L, Asken BM, Gorno-Tempini ML, Kramer JH, et al. Amyloid, Tau and metabolic PET correlates of cognition in early and late-onset alzheimer\u2019s disease. Brain. 2022;145:4489\u2013505.","journal-title":"Brain"},{"key":"1868_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-200808","volume":"80","author":"MD Fleisher","year":"2021","unstructured":"Devous Sr, Fleisher MD, Pontecorvo AS, Lu MJ, Siderowf M, Navitsky A. Relationships between cognition and neuropathological Tau in alzheimer\u2019s disease assessed by 18F flortaucipir PET. JAD. 2021;80:1091\u2013104.","journal-title":"JAD"},{"key":"1868_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jalz.2018.02.020","volume":"14","author":"JL Whitwell","year":"2018","unstructured":"Whitwell JL, Graff-Radford J, Tosakulwong N, Weigand SD, Machulda MM, Senjem ML, et al. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14:1005\u201314.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1868_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/acn3.51038","volume":"7","author":"KA Josephs","year":"2020","unstructured":"Josephs KA, Tosakulwong N, Graff-Radford J, Weigand SD, Buciuc M, Machulda MM, et al. MRI and flortaucipir relationships in alzheimer\u2019s phenotypes are heterogeneous. Ann Clin Transl Neurol. 2020;7:707\u201321.","journal-title":"Ann Clin Transl Neurol"},{"key":"1868_CR12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of Tau positron emission tomography as a prognostic marker in preclinical and prodromal alzheimer disease: A Head-to-Head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78:961\u201371.","journal-title":"JAMA Neurol"},{"key":"1868_CR13","doi-asserted-by":"crossref","unstructured":"Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA et al. Association of amyloid and Tau with cognition in preclinical alzheimer disease A longitudinal study. 2019;02114:915\u201324.","DOI":"10.1001\/jamaneurol.2019.1424"},{"key":"1868_CR14","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/brain\/awaa088","volume":"143","author":"M Malpetti","year":"2020","unstructured":"Malpetti M, Kievit RA, Passamonti L, Jones PS, Tsvetanov KA, Rittman T, et al. Microglial activation and Tau burden predict cognitive decline in alzheimer\u2019s disease. Brain. 2020;143:1588\u2013602.","journal-title":"Brain"},{"key":"1868_CR15","doi-asserted-by":"publisher","first-page":"e14398","DOI":"10.15252\/emmm.202114398","volume":"13","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S, et al. Tau PET correlates with different alzheimer\u2019s disease-related features compared to CSF and plasma p\u2010tau biomarkers. EMBO Mol Med. 2021;13:e14398.","journal-title":"EMBO Mol Med"},{"key":"1868_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of Solanezumab for mild dementia due to alzheimer\u2019s disease. N Engl J Med. 2018;378:321\u201330.","journal-title":"N Engl J Med"},{"key":"1868_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","volume":"77","author":"AM Wessels","year":"2020","unstructured":"Wessels AM, Tariot PN, Zimmer JA, Selzler KJ, Bragg SM, Andersen SW, et al. Efficacy and safety of lanabecestat for treatment of early and mild alzheimer disease. JAMA Neurol. 2020;77:199.","journal-title":"JAMA Neurol"},{"key":"1868_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00259-016-3601-4","volume":"44","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo MJ, Arora AK, Devine M, Lu M, Galante N, Siderowf A, et al. Quantitation of PET signal as an adjunct to visual interpretation of Florbetapir imaging. Eur J Nucl Med Mol Imaging. 2017;44:825\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1868_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jamaneurol.2020.5505","volume":"78","author":"M Lu","year":"2021","unstructured":"Lu M, Pontecorvo MJ, Devous MD, Arora AK, Galante N, McGeehan A, et al. Aggregated Tau measured by visual interpretation of flortaucipir positron emission tomography and the associated risk of clinical progression of mild cognitive impairment and alzheimer disease: results from 2 phase III clinical trials. JAMA Neurol. 2021;78:445.","journal-title":"JAMA Neurol"},{"key":"1868_CR20","first-page":"23","volume":"May 25","author":"K Schermelleh-Engel","year":"2003","unstructured":"Schermelleh-Engel K, Moosbrugger H, M\u00fcller H. Evaluating the fit of structural equation models: tests of significance and descriptive goodness-of-fit measures. Methods Psychol Res Online. 2003;25:23\u201374.","journal-title":"Methods Psychol Res Online"},{"key":"1868_CR21","doi-asserted-by":"crossref","unstructured":"Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of Tau PET, amyloid PET, and hippocampal volume on cognition in alzheimer disease. Neurology. 2018;91.","DOI":"10.1212\/WNL.0000000000006075"},{"key":"1868_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/jnnp-2021-328623","volume":"93","author":"J Lagarde","year":"2022","unstructured":"Lagarde J, Olivieri P, Tonietto M, Tissot C, Rivals I, Gervais P, et al. Tau-PET imaging predicts cognitive decline and brain atrophy progression in early alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2022;93:459\u201367.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1868_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13195-019-0518-8","volume":"11","author":"LA Digma","year":"2019","unstructured":"Digma LA, Madsen JR, Reas ET, Dale AM, Brewer JB, Banks SJ. Tau and atrophy: domain-specific relationships with cognition. Alzheimer\u2019s Res Therapy. 2019;11:65.","journal-title":"Alzheimer\u2019s Res Therapy"},{"key":"1868_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-021-00948-8","volume":"14","author":"D Biel","year":"2022","unstructured":"Biel D, Luan Y, Brendel M, Hager P, Dewenter A, Moscoso A, et al. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in alzheimer\u2019s disease. Alzheimer\u2019s Res Therapy. 2022;14:1\u201312.","journal-title":"Alzheimer\u2019s Res Therapy"},{"key":"1868_CR25","doi-asserted-by":"publisher","first-page":"103416","DOI":"10.1016\/j.nicl.2023.103416","volume":"38","author":"J Lu","year":"2023","unstructured":"Lu J, Zhang Z, Wu P, Liang X, Zhang H, Hong J, et al. The heterogeneity of asymmetric Tau distribution is associated with an early age at onset and poor prognosis in alzheimer\u2019s disease. NeuroImage: Clin. 2023;38:103416.","journal-title":"NeuroImage: Clin"},{"key":"1868_CR26","doi-asserted-by":"publisher","unstructured":"Anij\u00e4rv TE, Ossenkoppele R, Smith R, Binette AP, Collij LE, Behjat HH et al. Hemispheric Asymmetry of Tau Pathology is Related to Asymmetric Amyloid Deposition in Alzheimer\u2019s Disease. Neuroscience; 2025 [cited 2025 Jun 18]. Available from: http:\/\/biorxiv.org\/lookup\/doi\/https:\/\/doi.org\/10.1101\/2025.04.15.648728","DOI":"10.1101\/2025.04.15.648728"},{"key":"1868_CR27","doi-asserted-by":"publisher","first-page":"830","DOI":"10.2967\/jnumed.121.263694","volume":"63","author":"M Malpetti","year":"2022","unstructured":"Malpetti M, Joie RL, Rabinovici GD. Tau beats amyloid in predicting brain atrophy in alzheimer disease: implications for prognosis and clinical trials. J Nucl Med. 2022;63:830\u20132.","journal-title":"J Nucl Med"},{"key":"1868_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/ana.25406","volume":"85","author":"TM Harrison","year":"2019","unstructured":"Harrison TM, La Joie R, Maass A, Baker SL, Swinnerton K, Fenton L, et al. Longitudinal Tau accumulation and atrophy in aging and alzheimer disease. Ann Neurol. 2019;85:229\u201340.","journal-title":"Ann Neurol"},{"key":"1868_CR29","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1126\/scitranslmed.aau5732","volume":"12","author":"R La Joie","year":"2020","unstructured":"La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, et al. Prospective longitudinal atrophy in alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12:5732.","journal-title":"Sci Transl Med"},{"key":"1868_CR30","doi-asserted-by":"crossref","unstructured":"Scott MR, Hampton OL, Buckley RF, Chhatwal JP, Hanseeuw BJ, Jacobs HIL et al. Inferior Temporal Tau is associated with accelerated prospective cortical thinning in clinically normal older adults. NeuroImage. 2020;220.","DOI":"10.1016\/j.neuroimage.2020.116991"},{"key":"1868_CR31","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.neuroimage.2017.05.049","volume":"157","author":"MR LaPoint","year":"2017","unstructured":"LaPoint MR, Chhatwal JP, Sepulcre J, Johnson KA, Sperling RA, Schultz AP. The association between Tau PET and retrospective cortical thinning in clinically normal elderly. NeuroImage. 2017;157:612\u201322.","journal-title":"NeuroImage"},{"key":"1868_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neurobiolaging.2018.01.024","volume":"66","author":"SR Das","year":"2018","unstructured":"Das SR, Xie L, Wisse LEM, Ittyerah R, Tustison NJ, Dickerson BC, et al. Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake. Neurobiol Aging. 2018;66:49\u201358.","journal-title":"Neurobiol Aging"},{"key":"1868_CR33","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/alz.12252","volume":"17","author":"M Malpetti","year":"2021","unstructured":"Malpetti M, Jones PS, Tsvetanov KA, Rittman T, Swieten JC, Borroni B, et al. Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer\u2019s Dement. 2021;17:969\u201383.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1868_CR34","doi-asserted-by":"crossref","unstructured":"Clare L, Gamble LD, Martyr A, Sabatini S, Nelis SM, Quinn C et al. Longitudinal Trajectories of Quality of Life Among People With Mild-to-Moderate Dementia: A Latent Growth Model Approach With IDEAL Cohort Study Data. Isaacowitz DM, editor. The Journals of Gerontology: Series B. 2022;77:1037\u201350.","DOI":"10.1093\/geronb\/gbac022"},{"key":"1868_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13195-020-00699-y","volume":"12","author":"TM Liew","year":"2020","unstructured":"Liew TM. Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia. Alzheimer\u2019s Res Therapy. 2020;12:135.","journal-title":"Alzheimer\u2019s Res Therapy"},{"key":"1868_CR36","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1751-9004.2009.00224.x","volume":"3","author":"TE Duncan","year":"2009","unstructured":"Duncan TE, Duncan SC. The abc\u2019s of LGM: an introductory guide to latent variable growth curve modeling. Soc Pers Psychol Compass. 2009;3:979\u201391.","journal-title":"Soc Pers Psychol Compass"},{"key":"1868_CR37","doi-asserted-by":"crossref","unstructured":"Gleason CE, Zuelsdorff M, Gooding DC, Kind AJH, Johnson AL, James TT, et al. Alzheimer\u2019s disease biomarkers in black and non-Hispanic white cohorts: A contextualized review of the evidence. Alzheimer\u2019s & Dementia; 2021.","DOI":"10.1002\/alz.12511"},{"key":"1868_CR38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jamaneurol.2019.5154","volume":"77","author":"R Ossenkoppele","year":"2020","unstructured":"Ossenkoppele R, Lyoo CH, Jester-Broms J, Sudre CH, Cho H, Ryu YH, et al. Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological Tau in patients with alzheimer disease. JAMA Neurol. 2020;77:632.","journal-title":"JAMA Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01868-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01868-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01868-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:47:26Z","timestamp":1759754846000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01868-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1868"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01868-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocols of the interventional and observational trials were reviewed and approved by appropriate ethics committees as required by global trials. All trials were conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonization guideline on good clinical practice (World Medical Association, 1997). All patients provided written informed consent to participate in the trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Unrelated to this work, M.M. provides consultancy to Astex Pharmaceuticals. G.D.R. receives research funding from Avid Radiopharmaceuticals and has served as a scientific consultant to Eli Lilly, which manufacture the FTP tau PET radiotracer evaluated in this manuscript. Unrelated to this work, he receives research funds from GE Healthcare, Genentech and Life Molecular Imaging; has served as a paid scientific consultant to Alector, C2N, Genentech, Johnson & Johnson, Merck, Roche; serves as an Associate Editor for JAMA Neurology. MJP, LI and SS are employees and minor stockholders of Eli Lilly and Company. SR was an employee of Eli Lilly and Company when this work was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}